Formosa Laboratories (4746) Stock Overview
Engages in the manufacture and sale of active pharmaceutical ingredients (APIs) and ultraviolet absorbers in India, the Netherlands, Japan, Germany, Taiwan, China, Switzerland, the United States, Canada, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 5/6 |
4746 Community Fair Values
See what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more

Formosa Laboratories, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$52.70 |
| 52 Week High | NT$72.50 |
| 52 Week Low | NT$50.00 |
| Beta | 0.73 |
| 1 Month Change | -1.68% |
| 3 Month Change | -13.04% |
| 1 Year Change | -9.91% |
| 3 Year Change | -34.78% |
| 5 Year Change | -9.45% |
| Change since IPO | -42.66% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4746 | TW Pharmaceuticals | TW Market | |
|---|---|---|---|
| 7D | 2.5% | 1.6% | 4.2% |
| 1Y | -9.9% | 10.9% | 89.1% |
Return vs Industry: 4746 underperformed the TW Pharmaceuticals industry which returned 10.9% over the past year.
Return vs Market: 4746 underperformed the TW Market which returned 89.1% over the past year.
Price Volatility
| 4746 volatility | |
|---|---|
| 4746 Average Weekly Movement | 5.8% |
| Pharmaceuticals Industry Average Movement | 5.8% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in TW Market | 11.4% |
| 10% least volatile stocks in TW Market | 2.5% |
Stable Share Price: 4746 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 4746's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1985 | n/a | Chen-Yu Cheng | www.formosalab.com |
Formosa Laboratories, Inc., together with its subsidiaries, engages in the manufacture and sale of active pharmaceutical ingredients (APIs) and ultraviolet absorbers in India, the Netherlands, Japan, Germany, Taiwan, China, Switzerland, the United States, Canada, and internationally. It offers APIs in the areas of anticancer, vitamin D derivatives, anti-inflammatory and analgesic agents, immunomodulators, respiratory agents, cholesterol and phosphate binders, UV filter, iron deficiency anemia (IDA), CNS agents, MRI enhancing agents, steroids, antibiotics, and other areas; and injectables in the areas of IDA, MRI agents, oncology, and others. The company also provides contract development and manufacturing services, including recrystallization, filtration, dialysis, column purification, distillation, spray drying, and micronization; injectable manufacturing and secondary packaging, labeling, and serialization services; custom fermentation services; and peptide synthesis services.
Formosa Laboratories, Inc. Fundamentals Summary
| 4746 fundamental statistics | |
|---|---|
| Market cap | NT$6.34b |
| Earnings (TTM) | NT$441.11m |
| Revenue (TTM) | NT$4.85b |
Is 4746 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4746 income statement (TTM) | |
|---|---|
| Revenue | NT$4.85b |
| Cost of Revenue | NT$2.82b |
| Gross Profit | NT$2.03b |
| Other Expenses | NT$1.59b |
| Earnings | NT$441.11m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 3.67 |
| Gross Margin | 41.89% |
| Net Profit Margin | 9.09% |
| Debt/Equity Ratio | 40.4% |
How did 4746 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/18 08:34 |
| End of Day Share Price | 2026/04/17 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Formosa Laboratories, Inc. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | KGI Securities Co. Ltd. |
| Hsuan Chen | KGI Securities Co. Ltd. |
| Xiaowei Huang | Masterlink Securities Corp. |